Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
Authors:
Open Access
- 28 November 2024
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 816-827
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- AstraZeneca France
This publication has 23 references indexed in Scilit:
- 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetesEuropean Heart Journal, 2023
- Empagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2023
- Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre studyClinical Kidney Journal, 2023
- Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidenceKidney International, 2022
- Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2022
- Impact of Pretransplant and New-Onset Diabetes After Transplantation on the Risk of Major Adverse Cardiovascular Events in Kidney Transplant Recipients: A Population-based Cohort StudyTransplantation, 2021
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2019
- Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategiesNephrology Dialysis Transplantation, 2019
- Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT TrialAmerican Journal of Kidney Diseases, 2019
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016